Genentech/Novartis/Tanox Xolair
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
April 26 Pulmonary-Allergy Drugs Advisory Committee meeting at which Xolair was to be reviewed has been cancelled. The firms say they expect to launch the asthma and allergic rhinitis therapy omalizumab "in the latter part of 2001." The Xolair BLA was filed in June 200
You may also be interested in...
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.